HealthDay News — Most countries involved in clinical trials for US Food and Drug Administration approvals do not gain timely physical access to the medicines that they help evaluate, according to a ...

Countries lose measles elimination status when the same strain spreads for 12 months or more. If transmission continues into January (the 1-year mark) the US could lose the designation it has held for ...

HealthDay News — People paying out of pocket for Ozempic or Wegovy may soon see lower costs, as Novo Nordisk rolls out new price discounts for its popular GLP-1 medications. The company announced that ...

The investigational oral therapy combines doravirine, a non-nucleoside reverse transcriptase inhibitor, with islatravir, a nucleoside reverse transcriptase translocation inhibitor, in a single tablet ...

Agios Pharmaceuticals plans to share data from RISE UP with the Food and Drug Administration to support the approval of the sickle cell disease indication.

Study reveals self-administered, at-home hypnosis intervention reduces mean number of hot flashes, daily interference.

Lung ultrasound is acceptable diagnostic alternative to chest radiography in medical centers with appropriate clinical expertise.

Irene Papanicolas, PhD, from the Brown University School of Public Health in Providence, Rhode Island, and colleagues calculated premature mortality rates across US states and Washington, DC, for 2012 ...

Plozasiran is an apoC-III-directed small interfering ribonucleic acid designed to reduce levels of hepatic and serum apoC-III ...

With this approval, Thrombate III is the only antithrombin concentrate approved in both adults and pediatric patients with hereditary antithrombin deficiency.

Topline data were announced from a phase 3 trial evaluating giredestrant for the adjuvant treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ...

VS-041 is an oral inhibitor of matrix metalloproteinases shown to reduce cardiac fibrosis and improve diastolic heart function in preclinical HFpEF models.